ArticleBlood advances2023

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.

Aishath Naeem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.